These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 5384311)

  • 1. [Cerebrovascular diseases. 7. Dextran treatment during thrombotic diseases].
    Bygdeman S
    Lakartidningen; 1969 Oct; 66(40):4090-3. PubMed ID: 5384311
    [No Abstract]   [Full Text] [Related]  

  • 2. An evaluation of dextran in the prevention and treatment of thrombosis.
    Silver D
    Acta Chir Scand Suppl; 1968; 387():69-72. PubMed ID: 4240350
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of thrombotic diseases.
    Douglas AS
    Semin Hematol; 1971 Apr; 8(2):95-139. PubMed ID: 4396057
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: Mechanism of the antithrombotic action of dextran.
    Evans RJ; Gordon JL
    N Engl J Med; 1974 Mar; 290(13):748. PubMed ID: 4813751
    [No Abstract]   [Full Text] [Related]  

  • 5. Current treatment for thrombotic diseases.
    Cazenave JP; Wiesel ML; Hemmendinger S
    Agents Actions Suppl; 1984; 15():24-49. PubMed ID: 6091424
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-thrombotic therapy in diabetic patients: revisited.
    Stratmann B; Tschoepe D
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):253-5. PubMed ID: 21438800
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmaca which influence adhesion and aggregation possibilities of thrombocytes. A new way of anti-thrombosis therapy].
    Bygdeman S
    Nord Med; 1970 Jan; 83(3):88. PubMed ID: 5426054
    [No Abstract]   [Full Text] [Related]  

  • 8. Downstream Regulatory Element Antagonist Modulator (DREAM), a target for anti-thrombotic agents.
    Cho J
    Pharmacol Res; 2017 Mar; 117():283-287. PubMed ID: 28065857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental animal models of arterial thrombosis and the screening of platelet-inhibiting, anti-thrombotic drugs: a review.
    Philp RB
    Methods Find Exp Clin Pharmacol; 1979 Oct; 1(4):197-224. PubMed ID: 399655
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of activation of the fibrinolytic mechanism on experimental platelet-rich thrombi in rabbits.
    Hirsh J; Buchanan M; Glynn MF; Mustard JF
    J Lab Clin Med; 1968 Aug; 72(2):245-55. PubMed ID: 5671200
    [No Abstract]   [Full Text] [Related]  

  • 11. Some observations on the alteration of the adhesiveness of human blood platelets after infusion with low molecular weight dextran.
    Lal HB; Caroli RK; Sengupta D; Basumalik SN; Khan MA; Malik RN; Warrik HP
    J Assoc Physicians India; 1968 Aug; 16(8):523-7. PubMed ID: 5700157
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experimental studies of the preventive antithrombic action of Dextran 40].
    Kostrzewska E; Bergentz SE; Rudowski W
    Pol Tyg Lek; 1971 May; 26(21):788-90. PubMed ID: 5560122
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with low molecular weight dextran in patients with thrombocytosis.
    Tytgat GN; De Vreker RA; Lust A
    Acta Anaesthesiol Belg; 1968; 19(2):183-92. PubMed ID: 5746328
    [No Abstract]   [Full Text] [Related]  

  • 14. From molecules to medicine: new horizons in vascular biology and thrombosis (Part II).
    Preissner KT
    Thromb Haemost; 2008 Mar; 99(3):465. PubMed ID: 18327392
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of acute stroke with dextran 40.
    Gilroy J; Barnhart MI; Meyer JS
    JAMA; 1969 Oct; 210(2):293-8. PubMed ID: 5394364
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro methods of evaluating antithrombotics and thrombolytics.
    Mousa SA
    Methods Mol Biol; 2010; 663():1-28. PubMed ID: 20617413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy.
    Kazmier FJ
    Cardiovasc Clin; 1983; 13(2):321-33. PubMed ID: 6839327
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thrombelastographic data in an experimental study of the action of fibrinolytic agents].
    Izmaĭlova EF; Slobozhankina IK
    Patol Fiziol Eksp Ter; 1966; 10(4):18-22. PubMed ID: 5237733
    [No Abstract]   [Full Text] [Related]  

  • 19. [Dextran's anthrombotic properties. A review].
    Stadil F
    Ugeskr Laeger; 1970 Sep; 132(39):1813-6. PubMed ID: 4919233
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.
    Kim CW; Yun JW; Bae IH; Park YH; Jeong YS; Park JW; Chung JH; Park YH; Lim KM
    Thromb Res; 2011 Jun; 127(6):565-70. PubMed ID: 21420150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.